HORIZON (Follow-up)
A randomized double-blind, placebo-controlled, multicenter study assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease
- Medicine
- TQJ230
- Population
- ASCVD
- Phase
- III
- Starting year
- 2019
- More information
- Clinicaltrials.gov